Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Non-Small Cell Lung Cancer Metastatic

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Metastatic Non-small Cell Lung Cancers

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

CHRYSALIS

Chrysalis-2

PALOMA-3

PALOMA-2

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

COCOON

COPERNICUS

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

NeoLazer

MARIPOSA-2

MARIPOSA

LUCAS

AMAZE-lung

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

AMIGO-1

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

PLATINUM

CHAMELEON

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Impact of Lazertinib Dose Modification on Effectiveness and Safety

Lazertinib 160mg in EGFR T790M NSCLC

Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases

Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer

Early Access Program of Lazertinib in Republic of Korea

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer